Skip to main content

Burrows Scott L's Form 4 filing

Spyre Therapeutics, Inc. (SYRE) · filed Aug 5, 2026

Accession no.
0001636282-26-000100
Filed
Aug 5, 2026, 9:32 PM ET
Trade date
Aug 3, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $716.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Burrows Scott LCIK 0001853327Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 3, 2026Common StockMOption exerciseAcquired+7,500$14.50+$108,750105,494Direct
Aug 3, 2026Common StockSSaleDisposed−5,100$95.21−$485,571100,394Direct
Aug 3, 2026Common StockSSaleDisposed−2,300$96.30−$221,49098,094Direct
Aug 3, 2026Common StockSSaleDisposed−100$97.10−$9,71097,994Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 3, 2026Common StockMOption exerciseDisposed−7,500$0.00$0344,857Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)